(Q35721526)

English

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

scientific article published on 20 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane (English)

1 reference

Europe PubMed Central

9 August 2017

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Galina Velikova

6

object named as

Galina Velikova

0 references

3

object named as

Chris Twelves

1 reference

Europe PubMed Central

9 August 2017

object named as

Javier Cortes

10

0 references

5

object named as

Edith A Perez

1 reference

Europe PubMed Central

9 August 2017

author name string

Peter A Kaufman

1

1 reference

Europe PubMed Central

9 August 2017

Ahmad Awada

2

1 reference

Europe PubMed Central

9 August 2017

Louise Yelle

4

1 reference

Europe PubMed Central

9 August 2017

Martin S Olivo

7

1 reference

Europe PubMed Central

9 August 2017

Yi He

8

1 reference

Europe PubMed Central

9 August 2017

Corina E Dutcus

9

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

20 January 2015

1 reference

Europe PubMed Central

9 August 2017

full work available at URL

http://eprints.whiterose.ac.uk/108894/

content deliverer

White Rose Research Online

object has role

published version

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

0 references

Journal of Clinical Oncology

1 reference

Europe PubMed Central

9 August 2017

33

1 reference

Europe PubMed Central

9 August 2017

6

1 reference

Europe PubMed Central

9 August 2017

594-601

1 reference

Europe PubMed Central

9 August 2017

Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Treatment options for breast cancer resistant to anthracycline and taxane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

12 July 2018

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

25 September 2018

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

25 September 2018

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

25 September 2018

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

25 September 2018

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

25 September 2018

Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

25 September 2018

Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

25 September 2018

Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

25 September 2018

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4463422

15 November 2018

Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25605862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25605862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2013.52.4892

1 reference

Europe PubMed Central

9 August 2017

10.1200/JCO.2013.52.4892

0 references

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

2-s2.0-84923205214

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35721526&oldid=1672282817"